Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283


Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.

Dieudonné FX, Marion A, Marie PJ, Modrowski D.

J Bone Miner Res. 2012 Oct;27(10):2118-29. doi: 10.1002/jbmr.1650.


High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells.

Dieudonné FX, Marion A, Haÿ E, Marie PJ, Modrowski D.

Cancer Res. 2010 Jul 1;70(13):5399-408. doi: 10.1158/0008-5472.CAN-10-0090. Epub 2010 Jun 8.


Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma.

Marion A, Dieudonné FX, Patiño-Garcia A, Lecanda F, Marie PJ, Modrowski D.

Int J Cancer. 2012 Jun 1;130(11):2514-25. doi: 10.1002/ijc.26246. Epub 2011 Aug 16.


Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.

Orosco A, Fromigué O, Bazille C, Entz-Werle N, Levillain P, Marie PJ, Modrowski D.

Cancer Res. 2007 Apr 15;67(8):3708-15.


Wnt/β-catenin signaling regulates follicular development by modulating the expression of Foxo3a signaling components.

Li L, Ji SY, Yang JL, Li XX, Zhang J, Zhang Y, Hu ZY, Liu YX.

Mol Cell Endocrinol. 2014 Feb 15;382(2):915-25. doi: 10.1016/j.mce.2013.11.007. Epub 2013 Nov 15.


Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG.

Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29.


Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid-inducible kinase 1.

Dehner M, Hadjihannas M, Weiske J, Huber O, Behrens J.

J Biol Chem. 2008 Jul 11;283(28):19201-10. doi: 10.1074/jbc.M710366200. Epub 2008 May 16.


Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.

Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, Townsend CM Jr, Liu C, Evers BM.

Carcinogenesis. 2013 May;34(5):953-61. doi: 10.1093/carcin/bgt018. Epub 2013 Jan 25.


FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.

Liu H, Yin J, Wang H, Jiang G, Deng M, Zhang G, Bu X, Cai S, Du J, He Z.

Cell Signal. 2015 Mar;27(3):510-8. doi: 10.1016/j.cellsig.2015.01.001. Epub 2015 Jan 8.


Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.

Buondonno I, Gazzano E, Jean SR, Audrito V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I, Mungo E, Hattinger CM, Deaglio S, Kelley SO, Serra M, Riganti C.

Mol Cancer Ther. 2016 Nov;15(11):2640-2652. Epub 2016 Jul 27.


Antitumor Effect of Docetaxel in Osteosarcoma by the Inhibition of Wnt Signal Channel.

Wang DZ, Gao JF, Jing SF, Wei H, Huang XY, Li CD.

Drug Res (Stuttg). 2015 Nov;65(11):597-601. doi: 10.1055/s-0034-1395597. Epub 2014 Dec 16.


Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling.

Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q, Zuo G, Zhou L, Weng Y, Tang M, He T, Luo J.

Oncol Rep. 2013 Oct;30(4):1723-30. doi: 10.3892/or.2013.2658. Epub 2013 Aug 5.


Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC.

Preet R, Mohapatra P, Das D, Satapathy SR, Choudhuri T, Wyatt MD, Kundu CN.

Carcinogenesis. 2013 Feb;34(2):277-86. doi: 10.1093/carcin/bgs351. Epub 2012 Nov 5.


Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity.

Hoogeboom D, Essers MA, Polderman PE, Voets E, Smits LM, Burgering BM.

J Biol Chem. 2008 Apr 4;283(14):9224-30. doi: 10.1074/jbc.M706638200. Epub 2008 Feb 4.


Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.

Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr.

Blood. 2009 Apr 30;113(18):4319-30. doi: 10.1182/blood-2008-08-174300. Epub 2009 Feb 4.

Supplemental Content

Support Center